Topical 15% resorcinol for hidradenitis suppurativa: An uncontrolled prospective trial with clinical and ultrasonographic follow-up - 23/11/17
Drs Pascual and Encabo share senior authorship. |
|
Funding sources: None. |
|
Disclosure: Dr Pascual has been an advisory board member for Abbvie. Dr Jemec has been an investigator, consultant, and advisory board member for Abbvie and Novartis and has received unrestricted grants from Abbvie, Leo Pharma, and Novartis. In addition, Dr Jemec has been a speaker and investigator for Leo Pharma; a speaker for Galderma; an investigator for Regeneron; and an advisory board member for Janssen-Cilag, Inflarx, MSD, and Pierre-FAbre. Drs Encabo, Ruiz de Apodaca, Romero, and Selva have no conflicts of interest to declare. |
Vol 77 - N° 6
P. 1175-1178 - décembre 2017 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?